UroGen Pharma Ltd.·4

Jun 11, 9:14 AM ET

Schoenberg Mark 4

4 · UroGen Pharma Ltd. · Filed Jun 11, 2025

Insider Transaction Report

Form 4
Period: 2025-06-08
Schoenberg Mark
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2025-06-08+10,000158,540 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-06-0810,00010,000 total
    Ordinary Shares (10,000 underlying)
  • Sale

    Ordinary Shares

    2025-06-09$7.37/sh5,162$38,044153,378 total
Footnotes (3)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
  • [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
  • [F3]The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024.

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4